The U.K. is taking on a big pilot program with 500,000 people being remotely monitored at home using AI to analyze all the incoming data. The program by the National Health Service underscores where AI is likely to have the biggest impact in healthcare––non-consumption, or areas where there isn’t an affordable or convenient solution for consumers.

A peer-reviewed journal has put out a call for papers to publish in an upcoming special issue on cutting-edge uses of AI in early-phase drug development.

Researchers in China have developed a deep learning algorithm able to diagnose hyperlipidemia—elevated levels of cholesterol, fats and triglycerides in the bloodstream—in both blood and urine specimens, potentially giving clinicians more information with less expense to the patient.  

French researchers are designing an AI-based system to show diabetic patients their overall glycemic state in a readily understandable graphic display.

More than two-thirds of CV randomized clinical trial reports positively spin some aspect of the article to reflect favorable results that aren’t necessarily there, according to a study published in the May edition of JAMA Network Open.

The promised, less expensive insulin product from pharmaceutical company Eli Lilly has officially come to market, the company announced May 22.

The percentage of individuals offered access to their online medical record did not change from 2017 to 2018, according to the Office of the National Coordinator for Health Information Technology (ONC).

A Google-affiliated company is taking on clinical trials with the pharmaceutical industry, CNBC reported. The health and life sciences business of Google’s parent company Alphabet has launched strategic alliances with Novartis, Sanofi, Otsuka and Pfizer to work in the medical studies space.